Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | LPO | P22079 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27703181 | 0.80 | CHRNB2 (0.45) | CHRNB2CHRNA4LPOKMT2AALDH1A1 | |
| SCHEMBL2516063 | 0.75 | — | — | |
| SCHEMBL20195592 | 0.73 | — | — | |
| SCHEMBL4918147 | 0.72 | CHRNB2 (0.41) | CHRNB2CHRNA4LPOKMT2AKDM4E | |
| SCHEMBL2513335 | 0.71 | — | — | |
| SCHEMBL17115289 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL28150747 | 0.70 | CHRNB2 (0.50) | CHRNB2CHRNA4LPOKMT2AKDM4E | |
| SCHEMBL12701548 | 0.70 | CHRNB2 (0.50) | CHRNB2CHRNA4LPOKMT2AKDM4E | |
| SCHEMBL27788080 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL28178521 | 0.70 | CHRNB2 (0.50) | CHRNB2CHRNA4LPOKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101065502-B | Microarray-mediated diagnosis of herpes virus infection by monitoring host's differential gene expression upon infection | ATHLOMICS PTY LTD | 2012-06-06 | — | — | CN | disclosed |
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| CN-101535179-A | Activated carbon and method for producing the same | SUMITOMO CHEMICAL CO (JP) | 2009-09-16 | — | — | CN | disclosed |
| CN-101184691-A | Electric double layer capacitor | SUMITOMO CHEMICAL CO (JP) | 2008-05-21 | — | — | CN | disclosed |
| CN-101065502-A | Microarray-mediated diagnosis of herpes virus infection by monitoring host's differential gene expression upon infection | ATHLOMICS PTY LTD (AU) | 2007-10-31 | — | — | CN | disclosed |
| CN-1694621-A | Immunostimulatory G, U-containing oligoribonucleotides | COLEY PHARM GMBH (DE) | 2005-11-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | CHRNB2 240/4885CHRNA4 102/4885LPO 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.